Tenaya Therapeutics Company Insiders
TNYA Stock | USD 3.57 0.28 8.51% |
About 84 percent of Tenaya Therapeutics' insiders are selling. The analysis of the overall insider sentiment regarding Tenaya Therapeutics suggests that a fairly large number of insiders are terrified. Tenaya Therapeutics employs about 140 people. The company is managed by 11 executives with a total tenure of roughly 327 years, averaging almost 29.0 years of service per executive, having 12.73 employees per reported executive.
Tenaya Therapeutics' Insider Buying Vs Selling
16
Selling | Buying |
Latest Trades
2024-11-18 | Chihiro Saito | Disposed 2258 @ 2.12 | View | ||
2024-08-16 | Whittemore Tingley | Disposed 7428 @ 2.89 | View | ||
2024-03-05 | Timothy Hoey | Disposed 3300 @ 7 | View | ||
2024-02-20 | Timothy Hoey | Disposed 6569 @ 5.34 | View | ||
2024-02-16 | Timothy Hoey | Disposed 4681 @ 5.86 | View | ||
2024-02-12 | Group Gp Lp Column III | Acquired 2222222 @ 4.5 | View |
Monitoring Tenaya Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Tenaya |
Tenaya Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.4594) % which means that it has lost $0.4594 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8449) %, meaning that it created substantial loss on money invested by shareholders. Tenaya Therapeutics' management efficiency ratios could be used to measure how well Tenaya Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 30, 2024, Return On Tangible Assets is expected to decline to -0.76. In addition to that, Return On Capital Employed is expected to decline to -0.93. At present, Tenaya Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 293.9 M, whereas Non Current Assets Total are forecasted to decline to about 50.9 M.As of November 30, 2024, Common Stock Shares Outstanding is expected to decline to about 53.3 M. The current year's Net Loss is expected to grow to about (105.7 M)
Tenaya Therapeutics Workforce Comparison
Tenaya Therapeutics is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,977. Tenaya Therapeutics holds roughly 140 in number of employees claiming about 7% of equities under Health Care industry.
Tenaya Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tenaya Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tenaya Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Tenaya Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-12-01 | 8.0 | 8 | 1 | 272,000 | 2,258 |
2024-09-01 | 0.1111 | 1 | 9 | 25,000 | 19,539 |
2024-03-01 | 1.25 | 10 | 8 | 5,611,944 | 65,359 |
2023-03-01 | 21.0 | 21 | 1 | 5,098,338 | 28,125 |
2022-09-01 | 1.0 | 1 | 1 | 20,000 | 49,000 |
2022-06-01 | 12.0 | 12 | 1 | 476,724 | 1,353 |
2022-03-01 | 4.0 | 4 | 1 | 776,390 | 7,500 |
2021-09-01 | 0.3333 | 11 | 33 | 25,878,384 | 16,431,920 |
Tenaya Therapeutics Notable Stakeholders
A Tenaya Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Tenaya Therapeutics often face trade-offs trying to please all of them. Tenaya Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Tenaya Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Faraz MBA | Secretary CEO | Profile | |
Deepak MD | Chairman Founder | Profile | |
Saptarsi MD | Scientific Founder | Profile | |
Sheng Ding | Scientific Founder | Profile | |
Benoit Bruneau | Scientific Founder | Profile | |
Timothy Hoey | Chief Officer | Profile | |
Leone MBA | Chief Officer | Profile | |
Chihiro Saito | Senior Officer | Profile | |
KeeHong Kim | Chief Officer | Profile | |
Eric Olson | Scientific Board | Profile | |
Bruce Conklin | Scientific Founder | Profile |
About Tenaya Therapeutics Management Performance
The success or failure of an entity such as Tenaya Therapeutics often depends on how effective the management is. Tenaya Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Tenaya management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Tenaya management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.73) | (0.76) | |
Return On Capital Employed | (0.89) | (0.93) | |
Return On Assets | (0.73) | (0.76) | |
Return On Equity | (0.89) | (0.85) |
Please note, the presentation of Tenaya Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tenaya Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Tenaya Therapeutics' management manipulating its earnings.
Tenaya Therapeutics Workforce Analysis
Traditionally, organizations such as Tenaya Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Tenaya Therapeutics within its industry.Tenaya Therapeutics Manpower Efficiency
Return on Tenaya Therapeutics Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 886.3K | |
Net Loss Per Executive | 11.3M | |
Working Capital Per Employee | 634.6K | |
Working Capital Per Executive | 8.1M |
Complementary Tools for Tenaya Stock analysis
When running Tenaya Therapeutics' price analysis, check to measure Tenaya Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenaya Therapeutics is operating at the current time. Most of Tenaya Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenaya Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenaya Therapeutics' price. Additionally, you may evaluate how the addition of Tenaya Therapeutics to your portfolios can decrease your overall portfolio volatility.
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Share Portfolio Track or share privately all of your investments from the convenience of any device |